Congenital factor XI deficiency: an update.

  title={Congenital factor XI deficiency: an update.},
  author={Stefano Duga and O Salomon},
  journal={Seminars in thrombosis and hemostasis},
  volume={39 6},
Severe factor XI (FXI) deficiency is an injury-related bleeding disorder, common in Ashkenazi Jews (with two mutations prevailing), but rare worldwide (with heterogeneous mutations). In the past two decades, more than 220 mutations in the FXI gene have been reported in patients with FXI deficiency, of which 7 showed a founder effect. Inhibitors to FXI were described in patients with null-allele mutations, following exposure to plasma, FXI concentrates, or anti-RhD immunoglobulin. Treatment of… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 27 extracted citations

Inhibition of Factor XIa Reduces the Frequency of Cerebral Microembolic Signals Derived from Carotid Arterial Thrombosis in Rabbits.

The Journal of pharmacology and experimental therapeutics • 2017
View 6 Excerpts
Highly Influenced

Factor XI as a Therapeutic Target.

Arteriosclerosis, thrombosis, and vascular biology • 2016
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…